APA (7th ed.) Citation

MP, O., E, F., N, S., F, I., P, H., KC, C., . . . DM, W. (2022). Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA, 327(5), 432. https://doi.org/10.1001/jama.2021.24939

Chicago Style (17th ed.) Citation

MP, O'Brien, et al. "Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination Vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial." JAMA 327, no. 5 (2022): 432. https://doi.org/10.1001/jama.2021.24939.

MLA (9th ed.) Citation

MP, O'Brien, et al. "Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination Vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial." JAMA, vol. 327, no. 5, 2022, p. 432, https://doi.org/10.1001/jama.2021.24939.